SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Creative Media & Community Trust Corp. is a real estate investment trust that seeks to own, operate, and develop premier multifamily and creative office assets in vibrant and emerging communities throughout the United States. It operates through the following segments: Office, Hotel, and Lending. The Office segment consists of the rental of office space and other tenant services, including tenant reimbursements, parking, and storage space rental. The Hotel segment involves the operation of hotel properties. The Lending segment focuses on loans to small businesses. The company was founded in 1993 and is headquartered in Dallas, TX.

Creative Media & Community Trust

Creative Media & Community Trust ($CMCT) is trending due to its announcement of selling its lending division, which is expected to yield significant net cash proceeds. The community is focused on its low float, speculating about a potential short squeeze and parabolic move. Some traders are noting the setup for a potential breakout, while others caution about potential pump-and-dump schemes.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle ($CRCL) is trending as the stock reacts to strong earnings and a growing USDC circulation, with some community members discussing the potential for Cathie Wood to increase her position. Despite positive financial results, the stock initially experienced a dip, leading to debates about market irrationality and future price movement with the lockup period expiring soon.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending as chatter increases around a potential Nasdaq relisting and speculation about the company's earnings report. The community is also discussing Luckin's global expansion and comparing its growth and valuation to competitors like Starbucks. Some investors express concerns about market manipulation and the lack of communication from management.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

JMIA is trending as investors discuss its recent earnings results and future growth prospects, with much anticipation around the upcoming investor day. Community sentiment is mixed, with some questioning the stock's price action despite seemingly positive growth metrics. Bullish investors are focused on Jumia's potential in the African e-commerce market and the possibility of a significant breakout.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending following a strong earnings report and increased full-year guidance, with community members highlighting the potential for significant revenue growth and a rebrand to CorMedix Therapeutics. The community is actively discussing the impact of these results, and a conference call is scheduled where further details may be revealed. Broader discussions include the company's strategic investments and potential for shareholder value.

Leifras Co., Ltd. Engages in sport training, event and alliance & club activity support and healthcare activities. It provides services related to the organization and operations of sports schools and sports events for children and it also operate a robust social business sector, dispatching sports coaches to meet various community needs. The company was founded by Kiyotaka Ito on August 28, 2001 and is headquartered in Tokyo, Japan.

Leifras Co Ltd - ADR

LEIFRAS Co., Ltd. American Depositary Shares

LFS is trending due to a massive intraday surge, leading to speculation about the underlying catalyst and potential for further gains or a significant pullback. Community members are actively discussing potential sympathy plays in related stocks, particularly those with a Japan connection, and debating whether to chase the momentum or short the stock. Some traders point to low float and a recent contract as reasons for the move.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is trending as investors debate the company's prospects and certification timeline following mixed sentiment from analysts like Cramer. Community members are actively discussing potential FAA certification delays, the recent Blade acquisition, and Joby's partnership with Toyota, while some are drawing comparisons to Tesla's early investment phase. Contrarian views are also present, with some traders betting against the stock and citing concerns about cash burn and competition.

On Holding AG engages in the development and distribution of sports products such as footwear, apparel, and accessories for high-performance running, outdoor, all-day activities, and tennis. It sells its products worldwide through independent retailers and global distributors, its own online presence, and its own stores. The company was founded by David Allemann, Olivier Bernhard, and Caspar Coppetti in January 2010 and is headquartered in Zurich, Switzerland.

On Holding AG - Ordinary Shares Class A

On Holding AG

On Holding (ONON) is trending as investors discuss its strong Q3 performance and raised annual guidance, with some highlighting the company's growth relative to competitors like Nike. Community members are pointing to the brand's increasing visibility and premium pricing power, while also weighing potential impacts from tariffs and currency exchange rates. Bullish investors anticipate a continued climb towards higher price targets.

Memecoin on Injective taken over by the community.

Nonja

$NONJA is trending due to its strong community and potential within the Injective ecosystem, especially with the recent EVM mainnet launch on $INJ. The community believes $NONJA is undervalued and poised for significant gains, emphasizing its unique NFT collection and high burned liquidity. Many see it as the top meme coin on Injective, with potential for substantial returns as the Injective ecosystem grows.

Bill Holdings, Inc. engages in the provision of cloud-based software solutions. The firm simplifies, digitizes, and automates complex back-office financial operations for small and midsize businesses. Its software helps customers generate and process invoices, streamline approvals, send and receive payments, sync with their accounting systems and manage their cash. The company was founded by Rene Lacertea in April 2006 and is headquartered in San Jose, CA.

BILL Holdings Inc

Bill.com Holdings Inc

Bill.com is trending amid reports the company is exploring a potential sale, sending shares soaring in after-hours trading. Community discussions revolve around potential buyers, valuation comparisons to similar fintech acquisitions, and whether activist investor involvement will lead to a deal. Some are drawing parallels to other companies that explored sales without success, while others see the fintech sector as ripe for consolidation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ARTV Webcast Preview Summary (yesterday press release) 

The upcoming webcast will feature initial clinical and translational data from a remarkably robust cohort of 32 autoimmune patients treated with AlloNK + monoclonal antibody (mAb)—exceeding the market’s prior expectation of ~20 patients. This larger-than-expected sample size strengthens the credibility of the emerging safety and mechanistic data.

Key Highlights:

 • Safety &amp; Feasibility:
Early data in 32 patients show favorable tolerability with AlloNK + mAb, even with standard Cy/Flu conditioning, and importantly, in an outpatient rheumatology clinic setting. This underscores the ease-of-use and scalable potential of this off-the-shelf cell therapy.

 • Mechanism Confirmed:
High-sensitivity translational assays demonstrate uniform, deep B-cell depletion in all treated patients—10–50× more sensitive than conventional assays—validating the intended mechanism of action of AlloNK.

 • Reset-like Immune Recovery:
Post-treatment B-cell repopulation shows a dominant naïve and transitional phenotype, similar to what has been observed with autologous CD19 CAR-T therapies, suggesting a potential immune “reset” effect.

 • Focus on RA Unmet Need:
The webcast will also address the high unmet need in refractory rheumatoid arthritis (RA)—a major area where AlloNK’s outpatient, scalable approach could disrupt current treatment paradigms.

⸻

🚀 Potential Catalyst

The unexpected sample size (n=32) and planned data depth substantially raise the bar for clinical validation—well above prior street expectations of ~20 patients. Provided the webcast confirms safety and mechanistic strength, it may act as a near-term catalyst for the stock, adding to my position ahead of the event.

Good luck longs and looking forward to next week

(this info is not intended to be used for financial advise, please do your own research)

StockTwits for iOS

Artiva Biotherapeutics Inc

 Webcast Preview Summary (yesterday press release) 

The upcoming webcast will feature initial clinical and translational data from a remarkably robust cohort of 32 autoimmune patients treated with AlloNK + monoclonal antibody (mAb)—exceeding the market’s prior expectation of ~20 patients. This larger-than-expected sample size strengthens the credibility of the emerging safety and mechanistic data.

Key Highlights:

 • Safety & Feasibility:
Early data in 32 patients show favorable tolerability with AlloNK + mAb, even with standard Cy/Flu conditioning, and importantly, in an outpatient rheumatology clinic setting. This underscores the ease-of-use and scalable potential of this off-the-shelf cell therapy.

 • Mechanism Confirmed:
High-sensitivity translational assays demonstrate uniform, deep B-cell depletion in all treated patients—10–50× more sensitive than conventional assays—validating the intended mechanism of action of AlloNK.

 • Reset-like Immune Recovery:
Post-treatment B-cell repopulation shows a dominant naïve and transitional phenotype, similar to what has been observed with autologous CD19 CAR-T therapies, suggesting a potential immune “reset” effect.

 • Focus on RA Unmet Need:
The webcast will also address the high unmet need in refractory rheumatoid arthritis (RA)—a major area where AlloNK’s outpatient, scalable approach could disrupt current treatment paradigms.

⸻

🚀 Potential Catalyst

The unexpected sample size (n=32) and planned data depth substantially raise the bar for clinical validation—well above prior street expectations of ~20 patients. Provided the webcast confirms safety and mechanistic strength, it may act as a near-term catalyst for the stock, adding to my position ahead of the event.

Good luck longs and looking forward to next week

(this info is not intended to be used for financial advise, please do your own research)

Gurujoe

@Gurujoe Why is the company selling at a discount to cash despite the just granted fast track status for RA and encouraging data across the board. Not to mention the incredible people managing this company.

ALAS

StockTwits Web

 Why is the company selling at a discount to cash despite the just granted fast track status for RA and encouraging data across the board. Not to mention the incredible people managing this company.

John Smith

@johns45 true, market is putting zero  value on their autoimmune platform, if positive data is presented Wednesday AM, this stock should react very positively.  Despite having outstanding data in B cell L, they stopped the development to focus on autoimmune which makes me believe the open label data to be released will be very positive.

 true, market is putting zero  value on their autoimmune platform, if positive data is presented Wednesday AM, this stock should react very positively.  Despite having outstanding data in B cell L, they stopped the development to focus on autoimmune which makes me believe the open label data to be released will be very positive.